Pramlintide vs Semaglutide
Research Verdict
Pramlintide is the stronger research reference for the stated comparison criteria. Semaglutide: STEP trials (14.9% weight loss), SELECT CVOT (HR 0.80 MACE).
Quick Answers
Which is better, Pramlintide or Semaglutide?
Pramlintide is the stronger research reference for the stated comparison criteria. Semaglutide: STEP trials (14.9% weight loss), SELECT CVOT (HR 0.80 MACE).
What is the key difference between Pramlintide and Semaglutide?
Semaglutide is a GLP-1 agonist used primarily for weight management and T2DM; pramlintide is an amylin analog used as an insulin adjunct - different mechanisms, different primary endpoints, vastly different weight loss magnitudes.
Evidence Comparison
Semaglutide: STEP trials (14.9% weight loss), SELECT CVOT (HR 0.80 MACE). Pramlintide (Symlin): FDA approved for diabetes, ~2-3 kg weight loss in trials - primarily a glycemic agent, not a weight loss drug. Semaglutide is substantially stronger for metabolic outcomes.
Evidence Context Favoring Pramlintide
Type 1 diabetes research where pramlintide is the only approved amylin analog and insulin adjunct - semaglutide is not approved for T1DM.
Evidence Context Favoring Semaglutide
Weight management or T2DM research where semaglutide has the dominant efficacy and outcomes evidence.
Side-by-Side Snapshot
| Evidence grade | Pramlintide: Level A Semaglutide: Level A |
|---|---|
| Research status | Pramlintide: FDA Approved Semaglutide: FDA Approved |
| Primary category | Pramlintide: Weight Loss & Metabolic Semaglutide: Weight Loss & Metabolic |
| Cited studies | Pramlintide: 3 Semaglutide: 6 |